Veracyte Statistics
Total Valuation
Veracyte has a market cap or net worth of $2.69 billion. The enterprise value is $2.47 billion.
Important Dates
The next confirmed earnings date is Wednesday, November 6, 2024, after market close.
| Earnings Date | Nov 6, 2024 |
| Ex-Dividend Date | n/a |
Share Statistics
Veracyte has 76.81 million shares outstanding. The number of shares has increased by 3.15% in one year.
| Shares Outstanding | 76.81M |
| Shares Change (YoY) | +3.15% |
| Shares Change (QoQ) | +3.21% |
| Owned by Insiders (%) | 0.45% |
| Owned by Institutions (%) | 101.80% |
| Float | 76.46M |
Valuation Ratios
| PE Ratio | n/a |
| Forward PE | 44.22 |
| PS Ratio | 6.50 |
| Forward PS | 6.12 |
| PB Ratio | 2.37 |
| P/FCF Ratio | 66.96 |
| PEG Ratio | 1.13 |
Financial Ratio HistoryEnterprise Valuation
The stock's EV/EBITDA ratio is 76.80, with an EV/FCF ratio of 61.60.
| EV / Earnings | n/a |
| EV / Sales | 6.19 |
| EV / EBITDA | 76.80 |
| EV / EBIT | 343.50 |
| EV / FCF | 61.60 |
Financial Position
The company has a current ratio of 4.44, with a Debt / Equity ratio of 0.02.
| Current Ratio | 4.44 |
| Quick Ratio | 3.96 |
| Debt / Equity | 0.02 |
| Debt / EBITDA | 0.50 |
| Debt / FCF | 0.52 |
| Interest Coverage | 1,199.33 |
Financial Efficiency
Return on equity (ROE) is -4.88% and return on invested capital (ROIC) is 0.40%.
| Return on Equity (ROE) | -4.88% |
| Return on Assets (ROA) | 0.38% |
| Return on Capital (ROIC) | 0.40% |
| Revenue Per Employee | $490,281 |
| Profits Per Employee | -$66,308 |
| Employee Count | 815 |
| Asset Turnover | 0.33 |
| Inventory Turnover | 8.38 |
Taxes
| Income Tax | -750,000 |
| Effective Tax Rate | n/a |
Stock Price Statistics
The stock price has increased by +43.01% in the last 52 weeks. The beta is 1.67, so Veracyte's price volatility has been higher than the market average.
| Beta (5Y) | 1.67 |
| 52-Week Price Change | +43.01% |
| 50-Day Moving Average | 32.90 |
| 200-Day Moving Average | 25.54 |
| Relative Strength Index (RSI) | 58.79 |
| Average Volume (20 Days) | 626,126 |
Short Selling Information
The latest short interest is 3.10 million, so 4.04% of the outstanding shares have been sold short.
| Short Interest | 3.10M |
| Short Previous Month | 3.26M |
| Short % of Shares Out | 4.04% |
| Short % of Float | 4.05% |
| Short Ratio (days to cover) | 3.80 |
Income Statement
In the last 12 months, Veracyte had revenue of $399.58 million and -$54.04 million in losses. Loss per share was -$0.73.
| Revenue | 399.58M |
| Gross Profit | 270.41M |
| Operating Income | 7.20M |
| Pretax Income | -54.79M |
| Net Income | -54.04M |
| EBITDA | 32.18M |
| EBIT | 7.20M |
| Loss Per Share | -$0.73 |
Full Income StatementBalance Sheet
The company has $235.92 million in cash and $20.84 million in debt, giving a net cash position of $215.08 million or $2.80 per share.
| Cash & Cash Equivalents | 235.92M |
| Total Debt | 20.84M |
| Net Cash | 215.08M |
| Net Cash Per Share | $2.80 |
| Equity (Book Value) | 1.13B |
| Book Value Per Share | 14.76 |
| Working Capital | 248.77M |
Full Balance SheetCash Flow
In the last 12 months, operating cash flow was $50.33 million and capital expenditures -$10.20 million, giving a free cash flow of $40.13 million.
| Operating Cash Flow | 50.33M |
| Capital Expenditures | -10.20M |
| Free Cash Flow | 40.13M |
| FCF Per Share | $0.52 |
Full Cash Flow StatementMargins
Gross margin is 67.67%, with operating and profit margins of 1.80% and -13.52%.
| Gross Margin | 67.67% |
| Operating Margin | 1.80% |
| Pretax Margin | -13.71% |
| Profit Margin | -13.52% |
| EBITDA Margin | 8.05% |
| EBIT Margin | 1.80% |
| FCF Margin | 10.04% |
Dividends & Yields
Veracyte does not appear to pay any dividends at this time.
| Dividend Per Share | n/a |
| Dividend Yield | n/a |
| Dividend Growth (YoY) | n/a |
| Years of Dividend Growth | n/a |
| Payout Ratio | n/a |
| Buyback Yield | -3.15% |
| Shareholder Yield | -3.15% |
| Earnings Yield | -2.01% |
| FCF Yield | 1.49% |
Dividend DetailsAnalyst Forecast
The average price target for Veracyte is $35.67, which is 1.97% higher than the current price. The consensus rating is "Strong Buy".
| Price Target | $35.67 |
| Price Target Difference | 1.97% |
| Analyst Consensus | Strong Buy |
| Analyst Count | 6 |
| Revenue Growth Forecast (5Y) | n/a |
| EPS Growth Forecast (5Y) | n/a |
Stock ForecastsStock Splits
This stock does not have any record of stock splits.
| Last Split Date | n/a |
| Split Type | n/a |
| Split Ratio | n/a |
Scores
Veracyte has an Altman Z-Score of 10.41 and a Piotroski F-Score of 5.
| Altman Z-Score | 10.41 |
| Piotroski F-Score | 5 |